Avelumab plus axitinib combintion approved for untreated advanced kidney cancer in Scotland
The Sottish Medicine Consortium (SMC) have issued a final decision to recommend [...]
Biological markers of response for kidney cancer
To date, a reliable biomarker is yet to be discovered [...]
Funding approved for avelumab in combination with axitinib for untreated advanced kidney cancer
KCSN are formal consultants to NICE and part of the [...]
Evaluation of brain metastases in patients with kidney cancer treated with avelumab plus axitinib
In this video interview from Practice Update, Dr Eric Jonasch [...]
ASCO GU 2020: Immunotherapy combinations effective for brain metastases
Two small studies reported on patients whose kidney cancer had [...]
New first-line immunotherapy plus TKI combinations for metastatic kidney cancer
Approval of axitinib plus pembrolizumab and axitinib plus avelumab in [...]
Avelumab as a first- or second-line treatment for metastatic kidney cancer
A recent study looked at the efficacy and safety of [...]
Comparison of first-line immunotherapy combinations for advanced kidney cancer
In this paper, three clinical trials with immunotherapy combinations for [...]
European Commission approves avelumab plus axitinib combination for the first-line treatment of advanced kidney cancer
Based on the findings from the pivotal phase III JAVELIN [...]
ESMO 2019: Kidney cancer tumour shrinkage in patients who did not have surgery
This interview with Dr Monty Pal, Associate Professor from the [...]
